Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28385258 | 0.87 | AOC3 (0.42) | AOC3HCRTR2 | |
| SCHEMBL12356448 | 0.85 | GPR119 (0.47) | GPR119NPC1RAB9A | |
| SCHEMBL31104582 | 0.80 | AOC3 (0.53) | AOC3ACACB | |
| SCHEMBL2246355 | 0.77 | GPR119 (0.43) | AOC3GPR119 | |
| SCHEMBL26077252 | 0.74 | ALDH1A1 (0.45) | AOC3 | |
| SCHEMBL9910629 | 0.73 | GPR119 (0.40) | AOC3HCRTR2GPR119 | |
| SCHEMBL31180978 | 0.73 | AOC3 (0.36) | AOC3HCRTR2GPR119HDAC3HDAC1 | |
| SCHEMBL20148208 | 0.73 | AOC3 (0.41) | AOC3HCRTR2ACACB | |
| SCHEMBL23593426 | 0.72 | KDM1A (0.45) | ACACB | |
| SCHEMBL19864978 | 0.72 | SMO (0.43) | AOC3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134688-A1 | NOVEL COMPOUNDS | RIPK2, RIPK1, RIPK4 | AOC3 4660/4885HCRTR2 3622/4885GPR119 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.